Trial Profile
Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Indibulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 18 Jul 2012 Planned End Date changed from 1 Dec 2008 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Jul 2009 Planned end date changed from 1 Dec 2008 to 1 Feb 2009.